Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Virology and clinical sequelae of drug-resistant HBV in HIV-HBV-coinfected patients on highly active antiretroviral therapy.

Antiviral therapy - 1 Jan 2010

Thio Chloe L

Abstract excerpt

Several of the nucleoside/nucleotide analogues used to treat HIV also inhibit HBV replication, with lamivudine being the oldest of this group. Thus, prior to licensing of tenofovir, many HIV-HBV-coinfected individuals received lamivudine as the only drug active against HBV as part of an anti-HIV...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiretroviral Therapy, Highly Active
Share to Antiviral Agents
Share to Drug Resistance, Viral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatitis B

Share to Hepatitis B virus

Share to HIV Infections

Share to Nucleosides

Source

Open in PubMed Open full text

Identifiers

PMID: 20516569
DOI: 10.3851/IMP1553
PMCID: PMC2946104

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-20516569-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Virology and clinical sequelae of drug-resistant HBV in HIV-HBV-coinfected patients on highly active antiretroviral therapy.PMID 20516569Read ↗

Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy.Semantic proximity Read ↗

Comparison of the Mechanisms of Drug Resistance among HIV, Hepatitis B, and Hepatitis CSemantic proximity Read ↗

Major causes of antiviral drug resistance and implications for treatment of hepatitis B virus monoinfection and coinfection with HIV.Semantic proximity Read ↗

Prevalence and characterization of lamivudine-resistant hepatitis B virus mutations in HIV-HBV co-infected individuals.Semantic proximity Read ↗

Drug-resistant and immune-escape HBV mutants in HIV-infected hosts.Semantic proximity Read ↗

Fulminant hepatitis B due to a lamivudine-resistant mutant of HBV in a patient coinfected with HIV.Semantic proximity Read ↗

Hepatitis B virus drug resistance in HIV-1-infected patients taking lamivudine-containing antiretroviral therapy.Semantic proximity Read ↗

Low risk of lamivudine-resistant HBV and hepatic flares in treated HIV-HBV-coinfected patients from Côte d'Ivoire.Semantic proximity Read ↗

Molecular diagnosis and treatment of drug-resistant hepatitis B virus.Semantic proximity Read ↗

Influence of mutations in the hepatitis B virus genome on virus replication and drug resistance--implications for novel antiviral strategies.Semantic proximity Read ↗

Mutations associated with lamivudine-resistance in therapy-naïve hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients.Semantic proximity Read ↗

Virology and clinical sequelae of long-term antiviral therapy in a North American cohort of hepatitis B virus (HBV)/human immunodeficiency virus type 1 (HIV-1) co-infected patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.